


PHARMACEUTICAL 2020

APTINYX

Aptinyx Inc. Rank 56 of 358





RealRate

PHARMACEUTICAL 2020



Aptinyx Inc. Rank 56 of 358

The relative strengths and weaknesses of Aptinyx Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aptinyx Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 107% points. The greatest weakness of Aptinyx Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 209%, being 173% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	105,109
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,896
Liabilities, Non-Current	272
Other Assets	166
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	2,203
Other Revenues	3,669
Property and Equipment	1,204
Research and Development	44,330
Selling, General and Administrative Expense	18,952

Output Variable	Value in 1000 USD
Assets	106,479
Liabilities	5,168
Expenses	63,282
Revenues	3,669
Stockholders Equity	101,311
Net Income	-57,410
Comprehensive Net Income	-57,410
Economic Capital Ratio	209%

